gastro-esophageal reflux disease (GERD)
Conditions
Interventions
Vonoprazan 20mg orally once a day for two weeks,continued by Vonoprazan 10mg orally once a day for two weeks
Vonoprazan 20mg orally once a day for two weeks,continued by Esomeprazole 20mg orally once
Sponsors
Suita municipal hospital
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1) Patients who have freely given written consent to participating in the study after receiving a full explanation (written and oral) of the study. 2) Patients who had 8 or more of GerdQ score before the registration 3)Patients who were diagnosed with GERD
Exclusion criteria
Exclusion criteria: 1)Patients with warning signs such as vomiting, gastrointestinal bleeding (including findings of hematemesis, melena, and anemia),and sudden weight loss 2)Patients with a confirmed, or suspected, malignant lesion 3)Patients with a history of gastrointestinal resection or vagotomy 4)The patient with Irritable Bowel Syndrome (IBS) 5)Patients whose participation in this study would be contraindicated due to complications such as serious hepatic disease, renal disease, or cardiac disease. 6)Women who are pregnant or who may possibly be pregnant, and lactating mothers 7)treated with atazanavir sulfate, Rilpivirine Hydrochloride 8)Other patients whom the investigator considers unsuitable for admission to the study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the change in GerdQ total score before and 2,4 weeks after treatment with Vonoprazan and Esomeprazole | — |
Countries
Japan
Contacts
Public ContactKoji Nagaike
Suita municipal hospital Gastroenterology
Outcome results
None listed